Patents as Topic

• 

  Subject Areas on Research

  • Accountability in Patenting of Federally Funded Research 
  • Assessing biosimilarity and interchangeability of biosimilar products. 
  • Biosimilars: are they ready for primetime in the United States? 
  • Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options 
  • DNA patents and diagnostics: not a pretty picture. 
  • DNA sequence patents are not in the grave yet. 
  • Developing drugs for developing countries. 
  • Estimates of upper bounds and trends in nano-TiO2 production as a basis for exposure assessment. 
  • Expanding Access and Reducing Prices for Drugs to Prevent HIV: Should Government Enforce Its Patent Rights Against the Pharmaceutical Industry? 
  • Federal judge invalidates icosapent ethyl patents - but on the basis of a common statistical mistake. 
  • Generic and branded drugs for the treatment of people living with HIV/AIDS. 
  • Genomics. Genomics, biobanks, and the trade-secret model. 
  • Global health and university patents. 
  • How Logically Impossible Patents Block Biosimilars 
  • Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention 
  • Impact of Gene Patents and Licensing Practices on Access to Genetic Testing for Cystic Fibrosis 
  • Impact of Patents and Licensing Practices on Access to Genetic Testing for Inherited Susceptibility to Cancer: Comparing Breast and Ovarian Cancers to Colon Cancers 
  • Impact of gene patents and licensing practices on access to genetic testing for long QT syndrome. 
  • Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. 
  • Is Bayh-Dole Good for Developing Countries? Lessons from the U.S. Experience 
  • Letter to the Editor: Innovations in neurosurgery. 
  • Life Cycle Payback Estimates of Nanosilver Enabled Textiles under Different Silver Loading, Release, And Laundering Scenarios Informed by Literature Review. 
  • Moving Beyond "Isolated" Gene Patents 
  • National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. 
  • Novel medication targets for the treatment of alcoholism: preclinical studies. 
  • Opening up to precompetitive collaboration. 
  • Papers to patents. 
  • Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout. 
  • Physician-industry cooperation in the medical device industry. 
  • Prasugrel, a third generation thienopyridine and potent platelet inhibitor. 
  • Price differentiation and transparency in the global pharmaceutical marketplace. 
  • Racing for Academic Glory and Patents: Lessons from CRISPR 
  • Saving the Patent Law from Itself: Informal Remarks Concerning the Systemic Problems Afflicting Developed Intellectual Property Regimes 
  • Science and law. View from the bench: patents and material transfers. 
  • Science and the law. Working through the patent problem. 
  • Should the patent system for new medicines be abolished? 
  • Surgical invention and commercialization. 
  • Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. 
  • The Changing Life Science Patent Landscape 
  • The dangers of diagnostic monopolies. 
  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. 
  • The roles of patents and research and development incentives in biopharmaceutical innovation. 
  • Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea. 
  • US trade action threatens Brazilian AIDS programme. 
  • Use Patents Can Be Useful: The Case of Rescued Drugs 
  • Who owns the genome? 
• 

  Keywords of People

  • Ridley, David Blaine, Professor of the Practice of Business Administration, Duke Science & Society